Itasetron

Itasetron ( , ; developmental code names DAU-6215 and U-98079) is a selective serotonin 5-HT 3 receptor antagonist which was under development for the treatment of anxiety disorders, cognition disorders, nausea and vomiting, and psychotic…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Itasetron ( , ; developmental code names DAU-6215 and U-98079) is a selective serotonin 5-HT 3 receptor antagonist which was under development for the treatment of anxiety disorders, cognition disorders, nausea and vomiting, and psychotic disorders but was never marketed. It is taken orally. Itasetron was first described in the scientific literature by 1990.

The drug was under development by Boehringer Ingelheim. It reached phase 3 clinical trials for nausea and vomiting and phase 2 trials for anxiety disorders.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372021626 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.